Discontinued — last reported Q3 '16
An increase typically indicates recent acquisitions within the clinical research space, while a decrease suggests impairment charges or divestitures. Significant write-downs may signal a decline in the long-term growth prospects or profitability of the clinical trial services business.
This metric represents the portion of goodwill allocated to the Product Development segment, arising from historical acq...
Comparable to goodwill allocations in other Contract Research Organizations (CROs) or professional services firms that have grown through M&A activity.
iqv_segment_product_development_goodwill